Distinct differences in LC3+ EVs levels were observed in TB mouse models before and after immunotherapy, and the expression levels of LC3+ EVs for benign breast disease and breast cancer were clearly distinguished. This evidence concerns the gene MAP1LC3A and tuberculosis.